41 / 42
Some take home messages
• Monotherapy is the standard today in PD-L1>50%.
• Combinations must be better than monotherapy but not for all.
• Multiple remaining questions—?
• We need betters biomarkers.
• Different toxicities and more toxic in combo!!.
• Several phase 3 IO-CT and IO-IO now ongoing but close.